GRI Bio

GRI · NASDAQ

$1.46+$0.01 (+0.69%)TodayMarket closed · Oct 20, 6:48 PM ET

Prev close $1.45

GRI analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $156.57 (+10624.0% upside)

Low: $27.27
Now: $1.46
High: $294.00

Upgrades and downgrades

The latest rating actions, newest first

GRI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 10, 2026	Maintains	Buy	$10.00	17%
Ascendiant Capital	Aug 21, 2026	Maintains	Buy	$32.00 → $27.00	28%
Ascendiant Capital	Jun 1, 2026	Maintains	Buy	$40.00 → $32.00	28%
Ascendiant Capital	Mar 11, 2026	Maintains	Buy	$1,008.00 → $40.00	28%
Ascendiant Capital	Dec 8, 2025	Maintains	Buy	$35.00 → $36.00	28%

The case for and against

Updated Oct 15, 2026

Bull case

GRI Bio is viewed favorably because GRI-0621 produced encouraging Phase 2a IPF data, meeting primary, secondary, and exploratory endpoints while improving placebo-adjusted FVC by 99 ml as monotherapy and 139 ml with SoC, with no safety or tolerability concerns over 12 weeks. The thesis is strengthened by ERS ’26 biomarker evidence across 35 patients showing immune rebalancing, reduced lung injury, fibrosis resolution, and basement membrane repair, which supports a differentiated disease-modifying mechanism versus current antifibrotics that mainly slow progression. Financially, the company reported $11 million in cash and no debt in Q2, with liquidity seen as lasting into late-2027, while the large unmet need in IPF and the potential for GRI-0803 add further upside optionality.

Bear case

GRI Bio is viewed negatively because it remains a pre-revenue clinical-stage biotech with no commercial products, leaving its value dependent on uncertain trial outcomes and regulatory success for GRI-0621 and the still-preclinical GRI-0803. The company’s latest results show persistent losses, including a net loss of $1.6 million in fiscal Q2 2026 and $2.0 million in fiscal Q1 2026, while cash of about $10.9 million is only expected to fund operations into 2Q27, highlighting ongoing liquidity pressure and likely dilution risk. Even with IPF’s sizable addressable market, the combination of failed or inconclusive trials, funding uncertainty, delisting risk, and no revenue base makes the stock fundamentally fragile.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.